Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion - Episode 13
Additional Data Needs for BTK Inhibitors in CSU
Published on:
Panelists discuss how future research should focus on identifying biomarkers for patient selection, understanding long-term safety profiles, exploring combination therapy approaches, and determining optimal treatment duration with Bruton tyrosine kinase (BTK) inhibitors in chronic spontaneous urticaria (CSU).
Video content above is prompted by the following:
- What additional data, if any, is needed surrounding BTK inhibitors and CSU?
